APOA1 antibody (N-Term)
Quick Overview for APOA1 antibody (N-Term) (ABIN359573)
Target
See all APOA1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Specificity
- This antibody reacts to APOA1.
-
Purification
- Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human APOA1.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/50 - 1/100. Immunohistochemistry: 1/10 - 1/50.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- APOA1 (Apolipoprotein A-I (APOA1))
-
Alternative Name
- Apolipoprotein A I (APO AI)
-
Background
- Apolipoprotein A-I, is the major protein component of high density lipoprotein (HDL) in plasma. APOA1 promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the APOA1 gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.Synonyms: APOA1, Apo-AI, ApoA-I, ApoAI
-
Gene ID
- 335, 9606
-
UniProt
- P02647
-
Pathways
- Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism
Target
-